Phase 2 N=90 Image Parkinson's Disease Progression Study
Parkinson's Disease
Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=37 Amyloidopathy, Cholinopathy, Dopamine Responsiveness and Freezing of Gait in PD
Parkinson's Disease
Primary: L-DOPA Insensitivity — 5 Participants — p=0.00468
N/A N=2,448 First Presentation of Parkinson Disease Patients to Neurologist
Parkinson Disease
Primary: Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated — 403; 323; 73; 15 Participants
Phase 1 N=19 PF-06669571 In Subjects With Idiopathic Parkinson's Disease
Idiopathic Parkinson's Disease
Primary: Maximum Percent Change From Baseline in Movement Disorder Society-Sponsor Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III at Day 7…
Phase 3 N=336 Efficacy of Isradipine in Early Parkinson Disease
Parkinson Disease
Primary: Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score — 2.99; 3.26 score on a scale
Phase 3 N=427 Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Parkinson's Disease
Primary: Efficacy of 2 BIA 9-1067 (25 mg, and 50 mg) Compared With Placebo, When Administered With the Existing Treatment of L-DOPA Plus a DDCI (DOPA Decarboxylase Inhibitor)…
Phase 2 N=40 Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression
Parkinson Disease
Primary: Change in 18F-DTBZ Uptake in a Cohort of Parkinson's Disease Patients From Baseline to Month 36 — 12.95 SUVR
Phase 3 N=247 Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
IDIOPATHIC PARKINSON'S DISEASE
Primary: Change in the Sum of the Score From the Activities of Daily Living (ADL) Scale and Motor Examination in the Unified Parkinson's Disease Rating Scale (UPDRS) (Parts…
Phase 2 N=31 Parkinson's Disease Isradipine Safety Study
Parkinson's Disease
Primary: Tolerability of Isradipine Based on the Number of Participants That Complete the Study — 25 Participants
Phase 2 N=22 A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease
Parkinson's Disease
Primary: Number of Participants With Serious Adverse Events — 0; 0; 0 Participants
Phase 2 N=253 Dyskinesia in Parkinson's Disease (Study P04501)
Parkinson Disease · Movement Disorders · Central Nervous System Diseases
Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753
Phase 2 N=210 Pioglitazone in Early Parkinson's Disease
Parkinson's Disease
Primary: Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline to 44 Weeks — 4.42; 5.13; 6.25 units on a scale
Phase 2 N=137 A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
Parkinson Disease
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs) — 19; 21; 21; 21 Participants
Phase 2 N=142 Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression
Parkinson Disease
Primary: Change in the Ratio of the Specific Striatal [123I]B-CIT Uptake to the Nondisplaceable Striatal [123I]B-CIT Uptake Between the Two Images — -2.6; -4.7; -3.7; -6.9…
Phase 3 N=778 A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (P04938)
Parkinson Disease
Primary: Change From Baseline in Mean "Off" Time — -0.9; -0.9; -0.8; -0.8 Hours/day — p=0.8700
N/A N=9 Effect of Exercise in Parkinsonism
Parkinson's Disease · Drug-induced Parkinsonism
Primary: Change in Dopamine Transporter Imaging — 4.6; -15.9 % change in arbitrary intensity units
N/A N=30 The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease
Idiopathic Parkinson's Disease
Primary: Longitudinal Change of Brain Network Activity — 0.41; 0.61; 2.21; 3.61 Z-score in PDRP — p=0.84
Phase 3 N=346 Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients
Idiopathic Parkinson's Disease
Primary: Absolute Change in Absolute Time Spent 'Off' From Baseline to the End of Double-blind Maintenance Period — -1.13; -2.36 hours — p==0.0002
Phase 4 N=19 Vigor and the LDR in Parkinson Disease
Parkinson Disease
Primary: Tapping Speed Task - Experiment 1 — 110.52; 128.89; 138.43; 145.86 taps/min
N/A N=221 Evaluation of Clinical Decision Support System-mPDia for Neurodegenerative Parkinsonism Using MRI Images
Diagnoses Disease
Primary: Sensitivity of mPDia for the Diagnosis of Neurodegenerative Parkinsonism — 94.30 percentage
Phase 3 N=186 An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
Idiopathic Parkinson's Disease
Primary: Number of Subjects With at Least One Adverse Event During This Open-label Extension Study — 170 Subjects
N/A N=32 Prism Adaptation Treatment of Parkinson's Disease
Parkinson
Primary: Change in Postural Control - Reaction Time on the Limits of Stability Test (Smart Equitest Balance Master System) — 0.09; -0.02 Seconds
Phase 3 N=40 Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
Parkinson Disease · Orthostatic Hypotension
Primary: Change in Systolic Blood Pressure From Supine to Tilt at 3 Minutes — -24.22; -20.32 mmHg
Phase 3 N=174 Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
Parkinson's Disease (PD)
Primary: Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia — 0.97; 2.72 hours — p=0.0083
Phase 2 N=28 A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease
Advanced Parkinson's Disease
Primary: Levodopa Cmax Following First Dose on Day 1 — 2857.56; 2173.30 ng/mL
Phase 4 N=535 Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
Parkinson Disease
Primary: Change From Baseline in the Blinded Rater Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Month 15 — 0.3; 0.7 Units on a scale — p=0.6503
Phase 2 N=58 Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
Idiopathic Parkinson's Disease
Primary: UPDRS Part III OFF — -7.21; -6.91 units on a scale
N/A N=30 Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)
Parkinson's Disease
Primary: Safety: Time to Reach a 4 Point Increase (Worsening) in Unified Parkinson's Disease Rating Scale (UPDRS) Motor Score — 15; 14.1 months — p=0.968
N/A N=67 Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
Parkinson's Disease
Primary: AChE PET Neuroimaging — 0.0238; 0.0226 1/min — p=0.0009
N/A N=188 STEM-Parkinson's Disease
Parkinson Disease · Parkinson's Disease and Parkinsonism
Primary: Change in The International Parkinson and Movement Disorder Society Non-Motor Rating Scale (MDS-NMS) Total Score — -21.2; -18.3 score on a scale